

APR. 29 '2005 19:14 2028351755

CLARKBRODY

RECEIVED
CENTRAL FAX CENTER

#5898 P.001

APR 29 2005

CLARK
&
BRODY

FACSIMILE TRANSMISSION

SUITE 250
1090 VERMONT AVENUE, NW
WASHINGTON, DC 20005
TELEPHONE: 202-835-1111
FACSIMILE: 202-835-1755

TO:	COMPANY:
Examiner: KIRISHNAN, S., Art Unit 1723	U.S. Patent and Trademark Office
FAX NUMBER:	PHONE NUMBER:
703-872-9306	

From: Conrad J. Clark

Date: April 29, 2005

Total Number of Pages Including Cover Sheet: 9

Message: Please see attached Amendment.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the attached Amendment for U.S. Serial No. 10/698,404 is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Conrad J. Clark, Reg. No. 30,340

Type or print name of person signing certification.

Signature

Date: April 29, 2005



If you have not received the total number of pages, please call Tracy Boyden at (202) 835-1111. Thank you.

IMPORTANT - This message is intended solely to be used by the individual or entity to which it is addressed. It may contain information which is privileged, confidential and otherwise exempt by law from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to its intended recipient, you are herewith notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us by telephone immediately and return this communication to us at the

RECEIVED
CENTRAL FAX CENTER

APR 29 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Lou BLASETTI

Art Unit: 1723

Serial No.: 10/698,404

Examiner: Sun U. Kim

Filed: 11/03/2003

Attorney Dkt. No.: 70869-0066C

For: PRECIPITATION OF GROWTH FACTOR ENRICHED FIBRINOGEN
CONCENTRATE FROM PLATELET RICH PLASMAAMENDMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 29, 2005

Sir:

This responds to the Office Action dated October 29, 2004.

Amendments to the specification are submitted on page 2.

Amendments to the Abstract are submitted on page 3.

Amendments to the claims are submitted on page 4

Remarks are submitted on page 7.